ライフサイエンスコーパス: arteriovenous

1 oarterial, venovenous, venovenoarterial, and arteriovenous.

2 HMB we also measured muscle proteolysis (by arteriovenous (A-V) dilution).

3 d an AVF (n=295) or AVG (n=105) placed or no arteriovenous access (CVC group, n=71).

4 ation of dialysis, and time to thrombosis of arteriovenous access in hemodialysis patients.

5 I), and 20 of 24 eyes (83.3%) had peripheral arteriovenous anastomoses (Goldberg II) in addition.

6 Intrapulmonary arteriovenous anastomoses (IPAVA) have been known to exi

7 Blood flow through intrapulmonary arteriovenous anastomoses (IPAVAs) has been demonstrated

8 ia-induced blood flow through intrapulmonary arteriovenous anastomoses (QIPAVA ) are currently unknow

9 increased blood flow through intrapulmonary arteriovenous anastomoses (QIPAVA ) in healthy humans at

10 d the safety and efficacy of a central iliac arteriovenous anastomosis to alter the mechanical arteri

11 Arteriovenous anastomosis was associated with significan

12 icate that aplexone differentially regulates arteriovenous angiogenesis by targeting the HMG-CoA redu

13 79; P=0.017); among the 198 patients with an arteriovenous (AV) access at randomization, the risk was

14 Arteriovenous (AV) channels were identified by finding t

15 more likely to undergo surgery to create an arteriovenous (AV) fistula or place an AV graft.

16 ysis vascular access recommendations promote arteriovenous (AV) fistulas first; however, it may not b

17 nal drug release in the context of synthetic arteriovenous (AV) grafts used for chronic hemodialysis.

18 Synthetic arteriovenous (AV) hemodialysis grafts are plagued by hy

19 Arteriovenous (AV) malformation (AVM) is a devastating c

20 Retinal focal arteriolar narrowing, arteriovenous (AV) nicking, and microaneurysms/hemorrhag

21 A side-to-side arteriovenous (AV) shunt was created between the distal

22 (AVMs) are tortuous vessels characterized by arteriovenous (AV) shunts, which displace capillaries an

23 Using the arteriovenous balance technique, we studied the effect o

24 esence of unstable bradycardia or high-grade arteriovenous block in the absence of myocardial dysfunc

25 esence of unstable bradycardia or high-grade arteriovenous block without significant alteration in ca

26 orders characterized by localized lesions of arteriovenous, capillary, or lymphatic origin.

27 Application of pumpless arteriovenous carbon dioxide removal (AVCO2R) via percut

28 al strategies to reduce lung stretch include arteriovenous carbon dioxide removal (AVCO2R), and high

29 Initiation of extracorporeal arteriovenous carbon dioxide removal using the Novalung

30 enous nickings do not necessarily involve an arteriovenous compression.

31 drains visceral fat, we determined adipokine arteriovenous concentration differences across visceral

32 ing was examined by measuring differences in arteriovenous concentrations across the forearm muscle.

33 ight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on

34 se involving retention of normally transient arteriovenous connections, thereby generating AVMs.

35 ment and stabilization of normally transient arteriovenous connections.

36 vicular arteries and veins was measured with arteriovenous contrast ratio (AVCR) and contrast-to-nois

37 in a 1:1 ratio to undergo implantation of an arteriovenous coupler device plus current pharmaceutical

38 ssure reduced by 26.9 (SD 23.9) mm Hg in the arteriovenous coupler group (p<0.0001) and by 3.7 (21.2)

39 e reduced by 13.5 (18.8) mm Hg (p<0.0001) in arteriovenous coupler recipients and by 0.5 (15.8) mm Hg

40 (43%) of 195 patients screened were assigned arteriovenous coupler therapy (n=44) or normal care (n=3

41 Implantation of the arteriovenous coupler was associated with late ipsilater

42 In human eyes, similar arteriovenous crossings are risk factors for branch reti

43 tially regulated by the HMGCR pathway via an arteriovenous-dependent requirement for protein prenylat

44 rresponding experimental measurements of the arteriovenous difference across the abdominal subcutaneo

45 a combination of stable isotope labeling and arteriovenous difference measurements to elucidate pathw

46 Glucose metabolism was assessed using the arteriovenous difference technique, and molecular signal

47 clamp, TNF-alpha perfusion increased glucose arteriovenous differences (0.91 +/- 0.17 vs. 0.74 +/- 0.

48 chromatography-tandem mass spectrometry and arteriovenous differences adjusted for blood flow.

49 omprehensive biochemical characterization of arteriovenous differences has not yet been reported.

50 ox18/Vegfd and Sox7/Vegfd exhibit defects in arteriovenous differentiation.

51 be malformed and fragile, and they can lose arteriovenous differentiation.

52 l players in the complex regulation of human arteriovenous EC identity.

53 icial placenta strategies have been based on arteriovenous ECLS using the umbilical vessels with mode

54 involvement of PTPN14 in angiogenesis and/or arteriovenous fate, acting via EphrinB2 and ACVRL1/activ

55 Arteriovenous fistula (AVF) access improves survival in

56 mes have been established with the use of an arteriovenous fistula (AVF) at first hemodialysis.

57 CorMatrix wrapped around the outflow vein of arteriovenous fistula (AVF) at the time of creation coul

58 patients initiate hemodialysis (HD) with an arteriovenous fistula (AVF) in countries with universal

59 Arteriovenous fistula (AVF) is the preferred type of vas

60 Arteriovenous fistula (AVF) is the preferred vascular ac

61 Arteriovenous fistula (AVF) maturation failure is the pr

62 of the competing risk of death, high rate of arteriovenous fistula (AVF) maturation failure, and poor

63 Low rates of arteriovenous fistula (AVF) maturation prevent optimal f

64 and subsequently undergo placement of a new arteriovenous fistula (AVF) or arteriovenous graft (AVG)

65 enefit when initiating hemodialysis (HD) via arteriovenous fistula (AVF) or arteriovenous graft (AVG)

66 c variability in both incident and prevalent arteriovenous fistula (AVF) use among patients with ESRD

67 senting at least one cerebral or spinal pial arteriovenous fistula (AVF), and to describe their clini

68 g incident dialysis patients: (1) placing an arteriovenous fistula (AVF1st) as the initial access fol

69 asation (n = 14), pseudoaneurysm (n= 2), and arteriovenous fistula (n = 1).

70 ge, cerebrovascular malformations, and dural arteriovenous fistula affecting the basal ganglia, their

71 ux hemodialysis may benefit patients with an arteriovenous fistula and patients with diabetes and tha

72 Clinical practice guidelines recommend an arteriovenous fistula as the preferred vascular access f

73 ing primary radiocephalic or brachiocephalic arteriovenous fistula creation were randomly assigned (1

74 of MCP-1 occurs in the venous segment of an arteriovenous fistula in rodents, and this vasculopathic

75 nalyzed the changes that evolve in a femoral arteriovenous fistula in the rat.

76 Dural arteriovenous fistula is a very rare cause of myelitis t

77 Native arteriovenous fistula is one of the important routes for

78 The arteriovenous fistula is the preferred type of vascular

79 We conclude that this arteriovenous fistula model recapitulates the salient fe

80 effect on mortality of programmed VA (PVA), (arteriovenous fistula or PTFE graft) and nonprogrammed V

81 nd angiography revealed a pseudoaneurysm and arteriovenous fistula originating from the right interna

82 The primary endpoint was arteriovenous fistula patency at 3 months.

83 with local anaesthesia improved medium-term arteriovenous fistula patency.

84 evelopment include carotid body ablation and arteriovenous fistula placement.

85 alendar year with elective open AAA repairs, arteriovenous fistula repairs, or carotid endarderectomy

86 t pulsatile tinnitus caused by a small dural arteriovenous fistula revealed in computed tomography an

87 es after ligation injury and in failed human arteriovenous fistula samples after occlusion by dediffe

88 the lower risk of mortality associated with arteriovenous fistula use in hemodialysis patients is du

89 Arteriovenous fistula use increased only minimally, from

90 Arteriovenous fistula utilization at initial hemodialysi

91 model, venous neointimal hyperplasia in the arteriovenous fistula was also exacerbated.

92 jacent to vessels, and PSAs with concomitant arteriovenous fistula were referred to MC (n=145, 34%).

93 d by a kink, complete venous thrombosis, and arteriovenous fistula with pseudoaneurysm formation.

94 ssociations between type of vascular access (arteriovenous fistula, arteriovenous graft, and central

95 e prognosis when compared with those with an arteriovenous fistula, but the role of vascular access (

96 error, interobserver variability, bleeding, arteriovenous fistula, graft loss, and even death.

97 left heart failure, high cardiac output from arteriovenous fistula, hypoxic lung diseases, and metabo

98 n the venous segment of a murine model of an arteriovenous fistula, monocyte chemoattractant protein-

99 Finally, in a rat model of an arteriovenous fistula, we localized expression of MCP-1

100 lysis for the treatment of thrombosed native arteriovenous fistula.

101 edure for the treatment of thrombosed native arteriovenous fistula.

102 implemented an incentive if patients use an arteriovenous fistula.

103 as angiosarcomas might be correlated with an arteriovenous fistula.

104 nts, 20% of sarcomas arose at the site of an arteriovenous fistula.

105 er demonstrating right T7 to T8 spinal dural arteriovenous fistula.

106 n objective was the salvage of a functioning arteriovenous fistula.

107 nce angiography of his abdominal vessels and arteriovenous fistula.

108 Arteriovenous fistulae are the optimum form of vascular

109 y improved 3 month primary patency rates for arteriovenous fistulae.

110 ntima formation causes the failure of 60% of arteriovenous fistulas (AVFs) within 2 years.

111 are causes of tinnitus include cranial dural arteriovenous fistulas (DAVFs), which are usually small

112 x (CVR) in patients with lateral sinus dural arteriovenous fistulas (DAVFs).

113 Arteriovenous fistulas and pseudoaneurysms concerning in

114 Although arteriovenous fistulas are considered superior to grafts

115 vascular lesions such as pseudoaneurysms and arteriovenous fistulas associated with the internal pude

116 ces the frequency of early thrombosis of new arteriovenous fistulas but does not increase the proport

117 The relative rate of thrombosis of native arteriovenous fistulas for the highest quartile of intra

118 nts needing hemodialysis are advised to have arteriovenous fistulas rather than catheters because of

119 llow-up clinically and radiologically, dural arteriovenous fistulas should be kept in mind in the eti

120 , may contribute to the limited longevity of arteriovenous fistulas used for hemodialysis.

121 -dependent when waitlisted, individuals with arteriovenous fistulas were significantly less likely th

122 tained vascular injuries (pseudoaneurysms or arteriovenous fistulas) that can be treated electively o

123 Findings included aneurysms, ectasia, arteriovenous fistulas, and anomalous origins.

124 ures observed in dysfunctional, hemodialysis arteriovenous fistulas, and that venous neointimal hyper

125 In arteriovenous malformations and dural arteriovenous fistulas, ASL is very sensitive to detect

126 of patients 3 months after implantation) for arteriovenous fistulas, averaged across all patient popu

127 s thrombosis and dysfunction of hemodialysis arteriovenous fistulas, the latter caused, in part, by t

128 ith the low-flux group for the subgroup with arteriovenous fistulas, which constituted 82% of the stu

129 ears) with CKD undergoing predialysis AVF or arteriovenous graft (AVG) creation from 2004 to 2009, an

130 ysis (HD) via arteriovenous fistula (AVF) or arteriovenous graft (AVG) vs hemodialysis catheter (HC),

131 ment of a new arteriovenous fistula (AVF) or arteriovenous graft (AVG).

132 Arteriovenous graft stenosis leading to thrombosis is a

133 velopment in a porcine model of hemodialysis arteriovenous graft stenosis.

134 of intradialytic hypotension with prosthetic arteriovenous graft thrombosis after multivariable adjus

135 ven twice daily after the placement of a new arteriovenous graft until the primary outcome, loss of p

136 e of vascular access (arteriovenous fistula, arteriovenous graft, and central venous catheter) and ri

137 Utilization rates of AVF, arteriovenous graft, and intravascular hemodialysis cath

138 However, polytetrafluoroethylene arteriovenous grafts are prone to thrombosis, infection,

139 Arteriovenous grafts were created in wild-type or FSP-1-

140 Synthetic arteriovenous grafts, an important option for hemodialys

141 graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions o

142 The leading cause of failure of a prosthetic arteriovenous hemodialysis-access graft is venous anasto

143 nd both continuous venovenous and continuous arteriovenous hemodialysis.

144 ation is associated with acquisition of dual arteriovenous identity; increased Eph-B activity improve

145 Arteriovenous-lymphatic endothelial cell fates are speci

146 n about whether to treat an unruptured brain arteriovenous malformation (AVM) depends on a comparison

147 Congenital arteriovenous malformation (AVM) in the pelvic area is u

148 Arteriovenous malformation (AVM) is a fast-flow, congeni

149 A uterine arteriovenous malformation (AVM) is a rare cause of uter

150 Arteriovenous malformation (AVM) is an abnormal connecti

151 This arteriovenous malformation (AVM), which shunts nearly al

152 better outcome prediction for patients with arteriovenous malformation (AVM)-related intracerebral h

153 Capillary malformation-arteriovenous malformation (CM-AVM) is a blood and lymph

154 Capillary malformation-arteriovenous malformation (CM-AVM) is an autosomal domi

155 RASA1 mutations cause capillary malformation-arteriovenous malformation (CM-AVM); whether it also fun

156 n the international, multicentre Genetics of Arteriovenous Malformation (GEN-AVM) consortium.

157 We report on a case of pancreatic arteriovenous malformation (PAVM) that obliterated short

158 Renal arteriovenous malformation (RAVM) is a rare disease.

159 ovascular accident caused by a right pontine arteriovenous malformation and destruction of the right

160 Ang-2 therefore may contribute to arteriovenous malformation formation and subsequent blee

161 data regarding factors associated with brain arteriovenous malformation hemorrhage and different trea

162 al and genetic factors associated with brain arteriovenous malformation hemorrhage, as well as studie

163 reatment options in patients with unruptured arteriovenous malformation in the future.

164 Two recent studies in unruptured brain arteriovenous malformation management - ARUBA (a multice

165 cyclines to decrease the rate of spontaneous arteriovenous malformation rupture.

166 A1-related disorders (capillary malformation-arteriovenous malformation syndrome).

167 ing to a diagnosis of capillary malformation/arteriovenous malformation type 1.

168 ients (>/=18 years) with an unruptured brain arteriovenous malformation were enrolled into this trial

169 stroke in patients with an unruptured brain arteriovenous malformation who are allocated to either m

170 n 21 subjects with epilepsy, brain tumor, or arteriovenous malformation who had undergone IAP and MEG

171 cally associated with capillary malformation-arteriovenous malformation, but sporadic reports of lymp

172 rhage, including age at initial diagnosis of arteriovenous malformation, co-existing extranidal aneur

173 The recently published arteriovenous malformation-related intracerebral haemorr

174 nt feeding artery, which was consistent with arteriovenous malformation.

175 mab to treat the macular oedema in a case of arteriovenous malformation.

176 ted] as assessed by development of pulmonary arteriovenous malformation.

177 pared with those presenting with hemorrhagic arteriovenous malformation.

178 A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) aims to compare the

179 As brain arteriovenous malformations (AVM) and intracranial aneur

180 Brain arteriovenous malformations (AVMs) are an important caus

181 Cerebral arteriovenous malformations (AVMs) are common vascular m

182 Brain arteriovenous malformations (AVMs) are currently being t

183 Arteriovenous malformations (AVMs) are fragile direct co

184 Extracranial arteriovenous malformations (AVMs) are rare but dangerou

185 Arteriovenous malformations (AVMs) are tortuous vessels

186 Pelvic arteriovenous malformations (AVMs) are uncommon lesions

187 Arteriovenous malformations (AVMs) are vascular anomalie

188 Spinal arteriovenous malformations (AVMs) can lead to developme

189 Arteriovenous malformations (AVMs) in organs, such as th

190 age (ICH) for patients with unruptured brain arteriovenous malformations (AVMs) in the natural course

191 Because mutations in ALK1 cause arteriovenous malformations (AVMs), our findings suggest

192 es to life-threatening visceral and cerebral arteriovenous malformations (AVMs).

193 l hypervascularization and the appearance of arteriovenous malformations (AVMs).

194 after stereotactic radiosurgery for cerebral arteriovenous malformations (AVMs).

195 characterized by excessive angiogenesis with arteriovenous malformations (AVMs).

196 t connections between arteries and veins, or arteriovenous malformations (AVMs).

197 Brain arteriovenous malformations (BAVMs) are a rare but poten

198 Brain arteriovenous malformations (bAVMs) are an important cau

199 Brain arteriovenous malformations (BAVMs) can cause devastatin

200 nterventional treatment for unruptured brain arteriovenous malformations (bAVMs) is uncertain because

201 The pathogenesis of sporadic brain arteriovenous malformations (BAVMs) remains unknown, but

202 Within the past decade, pulmonary arteriovenous malformations (PAVMs) have evolved from ra

203 ss is a recognized complication of pulmonary arteriovenous malformations (PAVMs) that allow systemic

204 Mice mutant for Notch1 and Notch3 develop arteriovenous malformations and display hallmarks of the

205 In arteriovenous malformations and dural arteriovenous fist

206 f some other conditions, such as parenchymal arteriovenous malformations and intracerebral hemorrhage

207 y related Fox transcription factors, exhibit arteriovenous malformations and lack of induction of art

208 Congenital heart diseases with arteriovenous malformations carry a high risk of mortali

209 Tissue samples from patients with arteriovenous malformations displayed strong endothelial

210 or stroke in patients with unruptured brain arteriovenous malformations followed up for 33 months.

211 f preventive eradication of unruptured brain arteriovenous malformations remains uncertain.

212 areful angiographic assessment of individual arteriovenous malformations should be performed before e

213 Patients with unruptured arteriovenous malformations were found to be more suscep

214 icentre randomized trial of unruptured brain arteriovenous malformations) will be of major importance

215 Defects in the hyaloid vasculature, arteriovenous malformations, and coarctation of the aort

216 chronic obstructive pulmonary disease, brain arteriovenous malformations, and select cancers.

217 estigate the proper management of unruptured arteriovenous malformations, and the key factors in endo

218 s achieved satisfactory obliteration of deep arteriovenous malformations, but with increased actuaria

219 This resulted in defective angiogenesis and arteriovenous malformations, leading to embryonic lethal

220 st the hypothesis that, for unruptured brain arteriovenous malformations, there is no difference betw

221 levant for understanding the causes of human arteriovenous malformations, tumor angiogenesis, and dia

222 hese conditions include renal hemangiomas or arteriovenous malformations, ureteropelvic junction obst

223 on congenital heart disease and intracranial arteriovenous malformations.

224 ular assist devices (LVADs) and is caused by arteriovenous malformations.

225 well as the presence of multiple and massive arteriovenous malformations.

226 Final histology showed that 2 patients had arteriovenous malformations: one had a benign hemangioma

227 By arteriovenous measurements and histologic studies, local

228 ngiopoietins was measured by unique, dynamic arteriovenous measurements over the reperfused kidney.

229 Arteriovenous nicking was also associated with prevalent

230 Arteriovenous nicking was significantly associated with

231 riolar signs (focal arteriolar narrowing and arteriovenous nicking) and retinopathy lesions (retinal

232 se: retinopathy, focal arteriolar narrowing, arteriovenous nicking, and the arteriovenous ratio--the

233 Arteriovenous nickings (AVNs) in the retina are the caus

234 Arteriovenous nickings do not necessarily involve an art

235 n renal blood flow, GFR, O2 consumption, and arteriovenous O2 shunting.

236 segment close to a retinal arteriole without arteriovenous overlap were imaged by adaptive optics ima

237 ension (PVO2), venous oxygen content (CVO2), arteriovenous oxygen content difference (AVDO2), and loc

238 de tension difference (P(v - a)Co2) over the arteriovenous oxygen content difference (C(a - v)o2).

239 as the products of F and O2A, and F and the arteriovenous oxygen content difference (O2A-V), respect

240 and combined with oxygen uptake to calculate arteriovenous oxygen content difference.

241 ts had blunted exercise-induced increases in arteriovenous oxygen content difference.

242 tterns in oxygen uptake, cardiac output, and arteriovenous oxygen content difference.

243 additional assessment of cardiac output and arteriovenous oxygen content difference.

244 thy sedentary controls, the increase in peak arteriovenous oxygen difference did not.

245 ed from linearity between heart-rate and the arteriovenous oxygen difference, present in data from ex

246 alization increased peak arterial oxygen and arteriovenous oxygen difference, whereas exercise traini

247 P(bt)O2 and the product of CBF and cerebral arteriovenous oxygen tension difference (AVTO2), suggest

248 The mean arteriovenous P(O2) difference was 12+/-2 mm Hg.

249 xygen, chorioretinal vascular P(O2) and mean arteriovenous P(O2) differences decreased compared with

250 Retinal arteriovenous P(O2) differences during light flicker wer

251 Retinal arterial P(O2) and arteriovenous P(O2) differences increased with increasin

252 s in the chorioretinal vasculature P(O2) and arteriovenous P(O2) differences were determined.

253 breathing 100% O(2) affected intrapulmonary arteriovenous pathways during exercise.

254 P1 cytoplasmic domain is required for normal arteriovenous patterning, because arteries and veins cro

255 E) and venules (CRVE), and summarized as the arteriovenous ratio (AVR).

256 iations between MRI findings and the smaller arteriovenous ratio (per standard deviation decrease): p

257 ce or to find a difference in retinal vessel arteriovenous ratio between smokers and nonsmokers (P =

258 ar narrowing, arteriovenous nicking, and the arteriovenous ratio--the last based upon semiautomated m

259 At the systemic level, arteriovenous release of the proinflammatory cytokine in

260 the absence of both capillary expansion and arteriovenous remodeling in serially imaged individual T

261 etric changes in neocapillary morphogenesis, arteriovenous remodeling, and microvessel regression.

262 arterial input function was measured with an arteriovenous shunt and a beta-microprobe system.

263 ed the feasibility of IF measurement with an arteriovenous shunt and a coincidence counter in mice an

264 ive pulmonary disease underwent percutaneous arteriovenous shunt creation.

265 Fifteen patients underwent percutaneous arteriovenous shunt creation.

266 uidics-modeled vascular network in a femoral arteriovenous shunt in rats.

267 put and oxygen delivery , the creation of an arteriovenous shunt in the setting of severe chronic obs

268 Percutaneous creation of an arteriovenous shunt may increase oxygen delivery and, he

269 Parenchymal chamber pressure generated in an arteriovenous shunt model is a critical parameter that a

270 able vascular scaffold in an ex vivo porcine arteriovenous shunt model.

271 lls were tested in athymic rats in a femoral arteriovenous shunt model.

272 rsiro hybrid drug-eluting stent in a porcine arteriovenous shunt model.

273 roxia prevents or reduces blood flow through arteriovenous shunt pathways.

274 primary autonomic defenses against cold are arteriovenous shunt vasoconstriction and shivering.

275 oregulatory defences in humans are sweating, arteriovenous shunt vasoconstriction, and shivering.

276 THODS AND An ex vivo porcine carotid jugular arteriovenous shunt was established and connected to SYL

277 Femoral arteriovenous shunt was successfully established in all

278 al IF can be measured in mice with a femoral arteriovenous shunt.

279 h in collagen-coated grafts inserted into an arteriovenous shunt.

280 loped hallmarks of BAVMs, including cerebral arteriovenous shunting and vessel enlargement, by 3 week

281 lly decreased or eliminated exercise-induced arteriovenous shunting in all subjects at submaximal and

282 Once significant arteriovenous shunting was documented (bubble score = 2)

283 2 min; breathing room air, FIO2 = 0.209) and arteriovenous shunting was evaluated using saline contra

284 (EphB4 and Jagged-1), and showed evidence of arteriovenous shunting.

285 20) were obesity (31%), liver disease (23%), arteriovenous shunts (23%), lung disease (16%), and myel

286 l-grade tubing and catheters, assembled into arteriovenous shunts and implanted in pigs, remain paten

287 Patent foramen ovale and pulmonary arteriovenous shunts are associated with serious complic

288 rn is not suggestive for neoangiogenesis, as arteriovenous shunts from malignant tissues are responsi

289 ollagen-coated vascular grafts inserted into arteriovenous shunts in baboons, and reduced fibrin and

290 supplemented with bovine serum, implanted as arteriovenous shunts, and assessed for both mechanical s

291 tion, and most frequently caused by obesity, arteriovenous shunts, and liver disease.

292 bnormalities (retinal-choroidal anastomoses, arteriovenous shunts, increased permeability, dilation,

293 ibrin deposition on thrombogenic segments of arteriovenous shunts.

294 al floor of the dorsal aorta concurrent with arteriovenous specification and intersegmental vessel (I

295 suggest that not all of the effects of Hh on arteriovenous specification are mediated by VEGF.

296 included hypervascularization and defects in arteriovenous specification, as well as the presence of

297 terplay between Hh and VEGF signaling during arteriovenous specification.

298 development often occurs after placement of arteriovenous synthetic grafts used for hemodialysis.

299 r, the development of hyperplasia within the arteriovenous synthetic grafts was unchanged by treatmen

300 nges include venous-venous shunting, delayed arteriovenous transit, and delayed or absent choroidal p